|
Breast Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Significant associations with breast cancer were observed for rs13387042 and rs4415084 with OR (95% CI) per-allele 1.29 (1.00-1.66) and 0.83 (0.71-0.97), respectively.
|
27022606 |
2016 |
|
Malignant neoplasm of breast
|
|
0.800 |
GeneticVariation
|
BEFREE |
Significant associations with breast cancer were observed for rs13387042 and rs4415084 with OR (95% CI) per-allele 1.29 (1.00-1.66) and 0.83 (0.71-0.97), respectively.
|
27022606 |
2016 |
|
Malignant neoplasm of breast
|
|
0.800 |
GeneticVariation
|
BEFREE |
Five of the 17 SNPs were significantly associated (P ≤ 0.05) with overall breast cancer in the same direction as previously reported: rs13387042 (2q35/TNP1), rs4973768 (3p24/SLC4A7), rs2046210 (6q25/ESR1), rs1219648 (10q26/FGFR2), and rs4784227 (16q12/TOX3).
|
24510657 |
2015 |
|
Breast Carcinoma
|
|
0.800 |
GeneticVariation
|
GWASCAT |
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer.
|
25751625 |
2015 |
|
Breast Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We found that the rs13387042-2q35(G/A) SNP was associated with breast cancer risk only among postmenopausal women who never used hormone therapy [per A allele OR: 0.94 (95% confidence intervals, 0.74-1.20), 1.20 (0.94-1.53), and 1.49 (1.28-1.75) for current, former, and never hormone therapy users, respectively, Pinteraction 0.002] and premenopausal women who breastfed >12 months [OR: 1.01 (0.72-1.42), 1.19 (0.98-1.45), and 1.69 (1.26-2.26) for never, <12 months, and >12 months breastfeeding, respectively, Pinteraction 0.014].
|
26364163 |
2015 |
|
Malignant neoplasm of breast
|
|
0.800 |
GeneticVariation
|
BEFREE |
We found that the rs13387042-2q35(G/A) SNP was associated with breast cancer risk only among postmenopausal women who never used hormone therapy [per A allele OR: 0.94 (95% confidence intervals, 0.74-1.20), 1.20 (0.94-1.53), and 1.49 (1.28-1.75) for current, former, and never hormone therapy users, respectively, Pinteraction 0.002] and premenopausal women who breastfed >12 months [OR: 1.01 (0.72-1.42), 1.19 (0.98-1.45), and 1.69 (1.26-2.26) for never, <12 months, and >12 months breastfeeding, respectively, Pinteraction 0.014].
|
26364163 |
2015 |
|
Breast Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Five of the 17 SNPs were significantly associated (P ≤ 0.05) with overall breast cancer in the same direction as previously reported: rs13387042 (2q35/TNP1), rs4973768 (3p24/SLC4A7), rs2046210 (6q25/ESR1), rs1219648 (10q26/FGFR2), and rs4784227 (16q12/TOX3).
|
24510657 |
2015 |
|
Breast Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
These results indicate an additive effect of the TOX3 rs3803662 and 2q35 rs13387042</span> alleles for BC risk.
|
24532140 |
2014 |
|
Malignant neoplasm of breast
|
|
0.800 |
GeneticVariation
|
BEFREE |
These results indicate an additive effect of the TOX3 rs3803662 and 2q35 rs13387042</span> alleles for BC risk.
|
24532140 |
2014 |
|
Breast Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In conclusion, this meta-analysis demonstrated that the A allele of 2q35-rs13387042 is a risk factor associated with increased breast cancer susceptibility.
|
23976942 |
2013 |
|
Breast Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Our findings demonstrated that rs13387042-A allele is a risk-conferring factors for the development of BC, especially in Asians, Caucasians and Hispanic whites.
|
23894282 |
2013 |
|
Malignant neoplasm of breast
|
|
0.800 |
GeneticVariation
|
BEFREE |
We confirmed associations between rs13387042 (2q35), rs4973768 (SLC4A7), rs10941679 (5p12), rs2981582 (FGFR2), rs3817198 (LSP1), rs3803662 (TOX3), and rs6504950 (STXBP4) with breast cancer.
|
23893088 |
2013 |
|
Breast Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Seven SNPs were statistically significant (P ≤ 0.05) with the risk of overall breast cancer in the same direction as previously reported: rs10069690 (5p15/TERT), rs999737 (14q24/RAD51L1), rs13387042 (2q35/TNP1), rs1219648 (10q26/FGFR2), rs8170 (19p13/BABAM1), rs17817449 (16q12/FTO), and rs13329835 (16q23/DYL2).
|
23593120 |
2013 |
|
Malignant neoplasm of breast
|
|
0.800 |
GeneticVariation
|
BEFREE |
In conclusion, this meta-analysis demonstrated that the A allele of 2q35-rs13387042 is a risk factor associated with increased breast cancer susceptibility.
|
23976942 |
2013 |
|
Malignant neoplasm of breast
|
|
0.800 |
GeneticVariation
|
GWASDB |
Large-scale genotyping identifies 41 new loci associated with breast cancer risk.
|
23535729 |
2013 |
|
Malignant neoplasm of breast
|
|
0.800 |
GeneticVariation
|
BEFREE |
Seven SNPs were statistically significant (P ≤ 0.05) with the risk of overall breast cancer in the same direction as previously reported: rs10069690 (5p15/TERT), rs999737 (14q24/RAD51L1), rs13387042 (2q35/TNP1), rs1219648 (10q26/FGFR2), rs8170 (19p13/BABAM1), rs17817449 (16q12/FTO), and rs13329835 (16q23/DYL2).
|
23593120 |
2013 |
|
Breast Carcinoma
|
|
0.800 |
GeneticVariation
|
GWASCAT |
Large-scale genotyping identifies 41 new loci associated with breast cancer risk.
|
23535729 |
2013 |
|
Malignant neoplasm of breast
|
|
0.800 |
GeneticVariation
|
BEFREE |
Our findings demonstrated that rs13387042-A allele is a risk-conferring factors for the development of BC, especially in Asians, Caucasians and Hispanic whites.
|
23894282 |
2013 |
|
Breast Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We confirmed associations between rs13387042 (2q35), rs4973768 (SLC4A7), rs10941679 (5p12), rs2981582 (FGFR2), rs3817198 (LSP1), rs3803662 (TOX3), and rs6504950 (STXBP4) with breast cancer.
|
23893088 |
2013 |
|
Breast Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Confirmed BC risk SNPs rs17468277 (CASP8), rs1982073 (TGFB1), rs2981582 (FGFR2), rs13281615 (8q24), rs3817198 (LSP1), rs889312 (MAP3K1), rs3803662 (TOX3), rs13387042 (2q35), rs4973768 (SLC4A7), rs6504950 (COX11) and rs10941679 (5p12) were genotyped for 25 853 BC patients with the available follow-up; 62 other SNPs, which have been suggested as BC risk SNPs by a GWAS or as candidate SNPs from individual studies, were genotyped for replication purposes in subsets of these patients.
|
22532573 |
2012 |
|
Breast Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Blood samples can be used for determining the genotypes for 2q35-rs13387042 in patients for risk of breast cancer.
|
22287734 |
2012 |
|
Breast Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Overall, all of the five SNPs contributed to breast cancer susceptibility in a dominant genetic model (2q35, rs13387042: adjusted OR = 1.26, P = 0.006; 3q24.1, rs2307032: adjusted OR = 1.24, P = 0.005; 6q22.33, rs2180341: adjusted OR = 1.22, P = 0.006; 6q25.1, rs2046210: adjusted OR = 1.51, P = 2.40 × 10-8; 10q26.13, rs2981582: adjusted OR = 1.31, P = 1.96 × 10-4).
|
22269215 |
2012 |
|
Malignant neoplasm of breast
|
|
0.800 |
GeneticVariation
|
BEFREE |
Confirmed BC risk SNPs rs17468277 (CASP8), rs1982073 (TGFB1), rs2981582 (FGFR2), rs13281615 (8q24), rs3817198 (LSP1), rs889312 (MAP3K1), rs3803662 (TOX3), rs13387042 (2q35), rs4973768 (SLC4A7), rs6504950 (COX11) and rs10941679 (5p12) were genotyped for 25 853 BC patients with the available follow-up; 62 other SNPs, which have been suggested as BC risk SNPs by a GWAS or as candidate SNPs from individual studies, were genotyped for replication purposes in subsets of these patients.
|
22532573 |
2012 |
|
Malignant neoplasm of breast
|
|
0.800 |
GeneticVariation
|
BEFREE |
Blood samples can be used for determining the genotypes for 2q35-rs13387042 in patients for risk of breast cancer.
|
22287734 |
2012 |
|
Malignant neoplasm of breast
|
|
0.800 |
GeneticVariation
|
BEFREE |
Overall, all of the five SNPs contributed to breast cancer susceptibility in a dominant genetic model (2q35, rs13387042: adjusted OR = 1.26, P = 0.006; 3q24.1, rs2307032: adjusted OR = 1.24, P = 0.005; 6q22.33, rs2180341: adjusted OR = 1.22, P = 0.006; 6q25.1, rs2046210: adjusted OR = 1.51, P = 2.40 × 10-8; 10q26.13, rs2981582: adjusted OR = 1.31, P = 1.96 × 10-4).
|
22269215 |
2012 |